NovoCure (FRA:038) Change In Inventory : €3.1 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure Change In Inventory?

NovoCure's change in inventory for the quarter that ended in Mar. 2025 was €-3.6 Mil. It means NovoCure's inventory increased by €3.6 Mil from Dec. 2024 to Mar. 2025 .

NovoCure's change in inventory for the fiscal year that ended in Dec. 2024 was €2.5 Mil. It means NovoCure's inventory declined by €2.5 Mil from Dec. 2023 to Dec. 2024 .

NovoCure's Total Inventories for the quarter that ended in Mar. 2025 was €36.5 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. NovoCure's Days Inventory for the quarter that ended in Mar. 2025 was 89.65.

Inventory Turnover measures how fast the company turns over its inventory within a year. NovoCure's Inventory Turnover for the quarter that ended in Mar. 2025 was 1.02.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NovoCure's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.24.

NovoCure Change In Inventory Historical Data

The historical data trend for NovoCure's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Change In Inventory Chart

NovoCure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

-2.41

2.20

-4.10

-8.18

2.45

NovoCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Inventory	Get a 7-Day Free Trial															-4.28	1.75	1.71	3.28	-3.65

NovoCure Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.1 Mil.

NovoCure (FRA:038) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NovoCure's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	35.0075	/	35.631	*	365 / 4
	=	89.65

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

NovoCure's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	35.631	/	35.0075
	=	1.02

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NovoCure's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	35.0075	/	143.369
	=	0.24

NovoCure Change In Inventory Related Terms

Thank you for viewing the detailed overview of NovoCure's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines